• MYND Life Sciences (MYND) has announced plans to undertake a non-brokered private placement to raise gross proceeds of up to $3,500,000
  • Proceeds of the offering will be used to advance the company’s novel drug discovery platform and commercialize its diagnostic business unit
  • MYND Life Sciences is a medical biotech drug research and development company
  • MYND Life Sciences Inc. (MYND) opened trading at C$0.12 per share

MYND Life Sciences (MYND) has announced plans to undertake a non-brokered private placement to raise gross proceeds of up to $3,500,000.

The offering will close immediately after the closing of MYND’s acquisition of Tidal Care Inc. 

All shares issued are subject to a statutory four-month hold period. The offering is subject to final acceptance by the Canadian Securities Exchange.

Proceeds of the offering will be used to advance the company’s novel drug discovery platform, commercialize its diagnostic business unit and for general working capital.

MYND Life Sciences is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development and diagnostics.

MYND Life Sciences Inc. (MYND) opened trading at C$0.12 per share.

More From The Market Online

CCrest Labs receives Red Light Holland’s largest psilocybin order

Red Light Holland's (CSE:TRIP) largest shipment to date of 5 kilograms of psilocybin truffles has been received by CCrest Labs in Montreal.

Laurion Exploration to raise capital, and it’s worth every penny

Laurion Mineral Exploration (TSXV:LME) seeks to raise C$1.7 million through a flow-through private placement on a non-brokered basis.